Letter: increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than IBD.
Aliment Pharmacol Ther. 2019 Oct;50(7):834-835
Authors: Dai C, Jiang M, Sun MJ
PMID: 31532556 [PubMed – in process]